Trial Profile
A Phase III Multicentre, Parallel-group, Randomized, Placebo-controlled, Double-blind Clinical Trial to Study the Efficacy and Safety of MK-4117 in Japanese Subjects With Chronic Urticaria
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 05 May 2022
Price :
$35
*
At a glance
- Drugs Desloratadine (Primary)
- Indications Urticaria
- Focus Adverse reactions; Registrational; Therapeutic Use
- Sponsors Merck Sharp & Dohme; Organon
- 18 May 2016 Primary endpoint has been met. (Change From Baseline in the Sum Score of Pruritus/Itch and Rash Assessed by Investigator at Week 2), as per results presented at the 112th International Conference of the American Thoracic Society.
- 18 May 2016 Results presented at the 112th International Conference of the American Thoracic Society
- 27 Mar 2014 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.